MTSI · MACOM Technology Solutions Holdings, Inc.

The thesis

MACOM's chips for AI data-center optical links still support the case, but the shares have given back part of the early-October recovery; the fiscal fourth-quarter report, estimated for 5 November 2026, settles whether revenue reaches the guided $415–425 million. The shares closed at $291.33 on 14 October 2026 (adjusted daily closes), below the $301.64 earnings-day close of 6 August 2026 and the $301.63 close of 1 October 2026.

The narrative is maturing: the story is well known, 16 analysts carry an average target of $395.33 (StockAnalysis, 1 October 2026), and no company news since the 17 September 2026 product launch and the 18 September 2026 BMO upgrade has added a new reason to own the shares. The shares sit 28.9% under the $409.68 52-week high and 13.2% above the $257.43 close of 24 August 2026, the low of the post-earnings range.

The anchor is still the 6 August 2026 report. A weekly close above $301.64 would put the shares back through the earnings-day close; a weekly close below $257.43 would break the recovery.

Bullish and bearish views on MACOM Technology Solutions Holdings, Inc.

The bull case on MACOM Technology Solutions Holdings, Inc. (MTSI), in brief: Orders ran ahead of shipments. The bear case: The shares failed to hold the prior high.

Bull case

• Orders ran ahead of shipments. On the 6 August 2026 call MACOM reported a book-to-bill ratio of 1.6:1 and Data Center revenue of about $137.6 million, up from about $75.8 million a year earlier. Book-to-bill compares orders received with revenue shipped.
• The guide is a large step up. The $415–425 million fourth-quarter revenue guide followed $342.2 million in the third quarter. Reported revenue inside or above that range would show the order book converting.
• The product line widened. On 17 September 2026 MACOM introduced a 3.2-terabit optical chipset and said every product in the solution was available (company release via GlobeNewswire). The release gave no revenue figure.
• Analyst opinion has improved. BMO Capital moved MACOM to Outperform from Market Perform on 18 September 2026 and kept a $335 target. As of 5 October 2026, 13 of 16 analysts rated the shares Buy or Strong Buy and three rated them Hold, per search-aggregated consensus data.

Bear case

• The shares failed to hold the prior high. The close of $301.63 on 1 October 2026 matched the $301.64 earnings-day close and the shares have since closed at $291.33 on 14 October 2026. No weekly close above $301.64 has been recorded.
• Valuation is demanding. Simply Wall St cited a trailing price-to-earnings ratio of 90.3 on 25 September 2026 against 47.3 for the industry. A multiple that high leaves room for a slip if the November report only meets guidance.
• The shares remain far from their high. The $291.33 close is 28.9% under the $409.68 52-week high. The 14-day relative strength index (RSI, a 0–100 momentum gauge) was 52.0 on 14 October 2026, a neutral reading.
• Target spread is wide. BMO's $335 target is below the $395.33 average, and the range across analysts runs from $300 to $475 per Investing.com.
• Group selloffs hit the shares regardless of results. On 19 August 2026 the stock fell 7.8% to $269.98 on a sector move while company bookings were unchanged. MACOM was also removed from the Russell 1000 Value and Midcap Value indexes in the 2026 reconstitution.

Price setup

Adjusted daily closes show the shares at $291.33 on 14 October 2026, up 9.0% over three months. The reference points are the $409.68 52-week high, the $301.64 earnings-day close of 6 August 2026, the $269.98 close of 19 August 2026 and the $257.43 close of 24 August 2026.

Crowding evidence is moderate. The trailing multiple of 90.3 prices in continued growth, and an earnings date is about three weeks away. Neither a wide gap above a rising moving average nor insider selling into strength shows in the sources reviewed, and no SEC filings were posted in the latest check.

Catalysts, next 30 days

• ~28 October 2026, est.: large cloud-company quarterly reports. Capital-spending commentary from hyperscalers has moved MACOM with its peers, as on 19 August 2026.
• ~5 November 2026, est.: MACOM fiscal fourth-quarter and full-year 2026 results. The company had not announced a date as of 15 October 2026; the 2025 report came on 6 November 2025. Revenue tests the $415–425 million guide, the 60–61% adjusted gross margin and the roughly 50% forward Data Center growth frame.

What would change the view

The case breaks if fiscal fourth-quarter revenue lands under the $415 million low end of guidance, or if fiscal first-quarter guidance implies Data Center growth well under the roughly 50% frame. Book-to-bill falling toward 1.0 would show the order surge was a pull-in. On price, a weekly close below $257.43, the 24 August 2026 close, would erase the post-earnings recovery. Evidence that wafer supply from IQE limits Data Center shipments would also weaken the case.

What it trades with

MACOM trades with the optical and AI-interconnect group, including Coherent, Lumentum, Credo and Astera Labs. On 19 August 2026 the group sold off together on AI-valuation news and MACOM fell 7.8% to $269.98. Hyperscaler capital-spending reports around 28 October 2026 are the next shared catalyst, and the broader Nasdaq 100 reached record highs on 2 October 2026 (market news), so the shares carry exposure to AI sentiment and not only to company results.